Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.0% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,980 shares of the medical equipment provider’s stock after selling 485 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Zimmer Biomet were worth $323,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Chicago Partners Investment Group LLC raised its stake in shares of Zimmer Biomet by 3.3% in the 4th quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock valued at $349,000 after acquiring an additional 92 shares during the period. North Star Investment Management Corp. lifted its stake in shares of Zimmer Biomet by 16.6% during the first quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock worth $88,000 after purchasing an additional 95 shares in the last quarter. First Bancorp Inc ME boosted its position in shares of Zimmer Biomet by 5.3% in the first quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock worth $260,000 after buying an additional 100 shares during the period. Ballentine Partners LLC grew its stake in shares of Zimmer Biomet by 2.6% in the first quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 100 shares in the last quarter. Finally, Romano Brothers AND Company raised its holdings in shares of Zimmer Biomet by 1.1% during the 1st quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock valued at $1,256,000 after buying an additional 100 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.1 %

Shares of NYSE:ZBH opened at $106.34 on Thursday. The company’s fifty day moving average is $109.92 and its two-hundred day moving average is $115.72. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $133.90. The stock has a market capitalization of $21.66 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter in the prior year, the business earned $1.82 earnings per share. Zimmer Biomet’s quarterly revenue was up 3.9% on a year-over-year basis. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.02 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.90%. Zimmer Biomet’s payout ratio is currently 20.78%.

Analysts Set New Price Targets

Several brokerages have issued reports on ZBH. Robert W. Baird lowered their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Raymond James lowered their price target on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. JPMorgan Chase & Co. cut their price objective on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday. Canaccord Genuity Group lowered their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 10th. Finally, Oppenheimer cut their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $125.17.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.